



**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/579,149
Filing Date	January 19, 2007
First Named Inventor	Kortney L. Klinkel
Group Art Unit	1611
Examiner Name	Joseph S. Kudla

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	B1	3,279,918	10-18-1966	Gevaert Photo-Production N.V.	90	1	
	B2	3,297,710	1-10-1967	E.I. du Pont de Nemours & Co.	260	309	
	B3	4,089,747	5-16-1978	Eastman Kodak Co.	435	10	
	B4	4,423,046	12-27-1983	Sterling Drug Inc.	514	228.8	
	B5	4,466,976	8-21-1984	Schering Aktiengesellschaft	514	397	
	B6	4,585,771	4-29-1986	Schering Aktiengesellschaft	514	220	
	B7	4,705,855	11-10-1987	Rottapharm SpA	544	370	
	B8	4,721,670	1-26-1988	Fuji Photo Film Co.	435	28	
	B9	4,902,705	2-20-1990	UBE Industries, Ltd. et al.	514	397	
	B10	4,970,226	11-13-1990	Harbor Branch Oceanographic Institution, Inc.	514	397	
	B11	5,024,935	6-18-1991	Eastman Kodak Co.	435	7.1	
	B12	5,047,318	9-10-1991	Eastman Kodak Co.	435	5	
	B13	5,496,702	3-5-1996	Johnson & Johnson Chemical Diagnostics, Inc.	435	7.9	
	B14	5,514,550	5-7-1996	Johnson & Johnson Chemical Diagnostics, Inc.	435	6	
	B15	5,656,644	8-12-1997	SmithKline Beecham Corp.	514	341	
	B16	5,686,455	11-11-1997	SmithKline Beecham Corp.	514	256	
	B17	5,693,589	12-2-1997	Eastman Kodak Co.	503	227	
	B18	5,753,687	5-19-1998	Ontogen Corp.	514	396	
	B19	5,916,891	6-29-1999	SmithKline Beecham Corp.	514	256	
	B20	5,945,418	8-31-1999	Vertex Pharmaceuticals, Incorp.	514	248	
	B21	6,060,216	5-9-2000	Hitachi Chemical Co.	430	284.1	
	B22	6,117,609	9-12-2000	Brother Kogyu Kabushiki Kaisha	430	138	

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/579,149
	Filing Date	January 19, 2007
	First Named Inventor	Kortney L. Klinkel
	Group Art Unit	1611
	Examiner Name	Joseph S. Kudla

	B23	6,194,441	2-27-2001	Zeneca Ltd.	514	340	
	B24	6,268,370	7-31-2001	SmithKline Beecham Corp.	514	256	
	B25	6,521,655	2-18-2003	Ortho-McNeill Pharmaceuticals, Inc.	514	397	
	B26	2007/0123553	5-31-2007	Lorus Therapeutics Inc.	514	285	
	B27	2004/0127527	7-1-2004	Mitsuya et al.	514	365	
	B28	2004/0176601	9-9-2004	Goulet et al.	546	46	
	B29	2007/0105929	5-10-1997	Al-Qawasmeh	514	393	

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	B30	CA 2,351,694	7-22-1993	SmithKline Beecham Corp.	
	B31	EP 165588	12-27-1985	Fuji Photo Film Co. Ltd.	
	B32	JP 2002-275458	9-25-2002	Fukuoka Prefecture	Abstract
	B33	JP 2002-364578	12-18-2002	Hitachi Ltd.	Abstract
	B34	WO 1995/03297	2-2-1995	SmithKline Beecham Corp.	
	B35	WO 1996/18626	6-20-1996	F. Hoffman-La Roche AG Harmon	
	B36	WO 1998/27108	6-25-1998	Fujisawa Pharmaceutical Co. Ltd.	
	B37	WO 1999/01128	1-14-1999	Neurogen Corp.	
	B38	WO 2000/33836	6-15-2000	Ontogen Corp.	
	B39	WO 2003/004023	1-16-2003	Schering Aktiengesellschaft	
	B40	WO 1993/014081	7-22-1993	SmithKline Beecham Corp.	
	B41	WO 1998/027065	6-25-1998	Ontogen Corp.	
	B42	WO 2000/078761	12-28-2000	Sepracor Inc.	
	B43	WO 2002/046168	6-13-2002	Astrazeneca AB	
	B44	WO 2004/016086	2-26-2004	Lorus Therapeutics Inc.	
	B45	WO 2005/047266	11-15-2004	Lorus Therapeutics Inc.	

NON-PATENT DOCUMENTS		
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	B46	Abdel-Meguid <i>et al.</i> , "An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis," <i>Chemistry</i> , 1994, 33:11671-11677
	B47	Adams <i>et al.</i> , "Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity," <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11:2867-2870

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/579,149
Filing Date	January 19, 2007
First Named Inventor	Kortney L. Klinkel
Group Art Unit	1611
Examiner Name	Joseph S. Kudla

B48	Antolini <i>et al.</i> , "Analogues of 4,5-bis(3,5-dichlorophenyl)-2-trifluoromethyl-1H-imidazole as potential antibacterial agents," <i>Bioorg. Med. Chem. Lett.</i> , 1999, 9:1023-1028
B49	Armesto <i>et al.</i> , "A new site selective synthesis of benzoin esters, synthesis of symmetrically and unsymmetrically substituted benzils," <i>Synthesis</i> , 1988, 799-801
B50	Bhaduri <i>et al.</i> , "Potential Antifertility Agents. Synthesis of 2,4,5-Substituted Imidazoles", Central Drug Res. Inst. Lucknow, India, <i>Indian J. Chem.</i> , 1966, 4(9):419-420
B51	Botana <i>et al.</i> , " <i>p</i> -(1 <i>H</i> -Phenanthro[9,10- <i>d</i>]imidazol-2-yl)- Substituted Calix[4]arene, a Deep Cavity for Guest Inclusion", Departamento de Quimica Organica, Universidad Autonoma de Madrid, Spain, <i>Organic Letters</i> , 2004, 6(7):1091-1094
B52	Bu <i>et al.</i> , "A novel approach to synthesis of tricyanovinylthiophene for heterocyclic imidazole nonlinear optical chromophores," <i>Tetrahedron Lett.</i> , 1996, 37:7331-7334
B53	Chao <i>et al.</i> , Palladium catalyst in DMSO for the oxidation of tolans to benzils," <i>Polyhedron</i> , 2000, 1975-1983
B54	Chi <i>et al.</i> , "Palladium catalyst in DMSO for the oxidation of tolans to benzils," <i>Synth. Comm.</i> , 1994, 24(15), 2119-2122
B55	Cuenda, <i>et al.</i> , "Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38)," <i>EMBO J.</i> , 1997, 16:295-305
B56	Cuenda, <i>et al.</i> , "SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1," <i>Febs Lett.</i> , 1995, 364:229-33
B57	Database WPI, Section Ch. Week 199940, Derwent Publications Ltd, London, GB, Class B02, AN 1999-474062 (XP002268773) & JP 11 199582 (english abstract) A (Sagami Chem Res Cent), 27 July 1999
B58	Demirayak <i>et al.</i> , "Synthesis of Certain Derivatives of Ethyl α -[(phenanthro[9,10- <i>d</i>]imidazol-2-yl)phenoxy]alkanoate", <i>Acta Pharmaceutica Turcica</i> , 1989, 31(1):19-25
B59	Downey <i>et al.</i> , "Degradation of DNA by 1,10-phenanthroline," <i>Biochem Biophys Res Commun</i> , 1980, 93(1):264-70
B60	Fischer <i>et al.</i> , "Dissociation constants of the conjugate acids of substituted benzyl phenyl ketones and of alkyl-substituted benzophenones," <i>J. Am. Chem. Soc.</i> 1961, 83:4208-4210
B61	Gales <i>et al.</i> , "Characterization of pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999," <i>Clin. Infect. Dis.</i> , 2001, 32:S146-155
B62	Guijarro <i>et al.</i> , "The reaction of active zinc with organic bromides," <i>J. Am. Chem. Soc.</i> , 1999, 121:4155-4157
B63	Heerding <i>et al.</i> , "1,4-disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)," <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11:2061-2065
B64	Isikdag <i>et al.</i> , "QSAR of inhibitory activities by 2,4,5-trisubstituted imidazole derivatives on tubifex worms," <i>Acta Pharmaceutica Urica</i> 1995, 37(1):19-24

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/579,149
Filing Date	January 19, 2007
First Named Inventor	Kortney L. Klinkel
Group Art Unit	1611
Examiner Name	Joseph S. Kudla

B65	Krieg <i>et al.</i> , <i>Naturforsch.</i> 1967, 22b:132-141 (English translation)
B66	Kimura <i>et al.</i> , "Preparation of 4-(4,5-diphenyl-1H-imidazol-2-yl)benzaldehyde and its Practical Synthetic Use in the Synthesis of Unsymmetrically Substituted Imidazoles", Department of Chemistry, Okayama University, Okayama Japan, ITE Letters on Batteries, New Technologies & Medicine, 2002, 3(1), pp. 30-34
B67	Lee <i>et al.</i> , "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis," <i>Nature</i> , 1994, 327:739-745
B68	Lewis J.R., "Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids," <i>Nat. Prod. Rep.</i> , 1998, 15:371-395
B69	Lewis J.R., "Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids," <i>Nat. Prod. Rep.</i> , 1998, 15:417-437
B70	Lewis J.R., "Miscellaneous alkaloids: Amaryllidaceae, sceletium, muscarine, imidazole, oxazole, peptide miscellaneous alkaloids," <i>Nat. Prod. Rep.</i> , 1999, 16:389-416
B71	Liu <i>et al.</i> , "Enantiomeric ruthenium(II) complexes binding to DNS: binding modes and enantioselectivity," <i>JBIC</i> , 2000, 5:119-128
B72	LoGrasso <i>et al.</i> , "Kinetic mechanism fro p38 MAP kinase," <i>Biochemistry</i> , 1997, 36:10422-10427
B73	Mann <i>et al.</i> , "1,10-phenanthroline inhibits glycosylphosphatidylinositol anchoring by preventing phosphoethanolamine addition to glycosylphosphatidylinositol anchor precursors," <i>Biochemistry</i> , 2001, 40(5):1205-13
B74	McLay <i>et al.</i> , "The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritis efficacy," <i>Bioorg. Med. Chem.</i> , 2001, 9:537-554
B75	Moylan <i>et al.</i> , "Synthesis and Nonlinear Optical Properties of Donor-Acceptor Substituted Triaryl Azole Derivatives", Almaden Res. Cent. IBM, San Jose, CA, USA, Chemistry of Materials, 1993, 5(10):1499-1508
B76	Pan <i>et al.</i> , "DNA-binding proteins as site-specific nucleases," <i>Mol Microbiol</i> , 1994, 12(3):335-42
B77	Sarshar <i>et al.</i> , "2,4,5-trisubstituted imidazoles: Novel nontoxic modulators of P-glycoprotein mediated multidrug resistance Part 1," <i>Bioorg. Med. Chem. Lett.</i> , 2000, 10:2599-2601
B78	Sarshar <i>et al.</i> , "Imidazole libraries on solid support," <i>Tetrahedron Lett.</i> 1996, 37:835-838
B79	Shulman <i>et al.</i> , "Action of 1,10-phenanthroline transition metal chelates on P388 mouse lymphocytic leukaemic cells," <i>Chem Biol Interact</i> , 1977, 16(1): 89-99
B80	Sigman <i>et al.</i> , "Oxygen-dependent cleavage of DNA by the 1,10-phenanthroline cuprous complex," <i>J Biol Chem</i> , 1979, 254(24):12269-72
B81	Springman <i>et al.</i> , "Zinc content and function in human fibroblast collagenase," <i>Biochemistry</i> , 1995, 34(48):15713-20
B82	Tanaseichuk <i>et al.</i> , Uch. Zap., Mord. Univ. (1971), No. 81, 95-7 (From: Ref. Zh., Khim. 1972, Abstr. No. 12zh318 (English translation)
B83	Xu <i>et al.</i> , "Effects of the ancillary ligands of polypyridyl ruthenium(II) complexes on the DNA-binding behaviors," 2003, 27:1255-1263

Examiner Signature:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use as many sheets as necessary)

Complete if Known

Examiner Name	Joseph S. Kudla
---------------	-----------------

[illegible]

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.